Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.

Publication

Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.

Journal Paper/Review - May 10, 2022

Polymeris Alexandros A, Zietz Annaelle, Schaub Fabian, Meya Louisa, Traenka Christopher, Thilemann Sebastian, Wagner Benjamin, Hert Lisa, Altersberger Valerian L, Seiffge David Julian, Lyrer Flurina, Dittrich Tolga, Piot Ines, Kaufmann Josefin, Barone Lea, Dahlheim Ludvig, Flammer Sophie, Avramiotis Nikolaos S, Peters Nils, De Marchis Gian Marco, Bonati Leo H, Gensicke Henrik, Engelter Stefan T, Lyrer Philippe A

Citation

Polymeris A, Zietz A, Schaub F, Meya L, Traenka C, Thilemann S, Wagner B, Hert L, Altersberger V, Seiffge D, Lyrer F, Dittrich T, Piot I, Kaufmann J, Barone L, Dahlheim L, Flammer S, Avramiotis N, Peters N, De Marchis G, Bonati L, Gensicke H, Engelter S, Lyrer P. Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation. Eur Stroke J 2022; 7:221-229.

Type

Journal Paper/Review (English)

Journal

Eur Stroke J 2022; 7

Publication Date

May 10, 2022

Issn Electronic

2396-9881

Pages

221-229

Brief description/objective

Data on the safety and effectiveness of once-daily (QD) versus twice-daily (BID) direct oral anticoagulants (DOAC) in comparison to vitamin K antagonists (VKA) and to one another in patients with atrial fibrillation (AF) and recent stroke are scarce.